Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Axsome Therapeutics Inc Market Cap
From what 10 stock analysts predict, the share price for Axsome Therapeutics Inc (AXSM) might increase by 59.44% in the next year. This is based on a 12-month average estimation for AXSM. Price targets go from $90.00 to $180.00. The majority of stock analysts believe AXSM is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 10 Wall Street analysts have assigned AXSM 9 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect Axsome Therapeutics Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on AXSM. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| graig suvannavejh Mizuho Securities | Buy | $90.0 | maintained | Feb 13, 2024 |
| ashwani verma UBS | Buy | $111.0 | initiatedcoverage | Feb 6, 2024 |
| leonid timashev RBC Capital | Buy | $126.0 | initiatedcoverage | Jan 25, 2024 |
| matthew kaplan Ladenburg Thalmann & Co. | Buy | $173.0 | maintained | Jan 16, 2024 |
| david amsellem Piper Sandler | Buy | $113.0 | reiterated | Jan 16, 2024 |
| jason gerberry Bank of America Securities | Hold | $95.0 | reiterated | Jan 11, 2024 |
| ram selvaraju H.C. Wainwright | Buy | $180.0 | reiterated | Jan 5, 2024 |
| david hoang SMBC Nikko | Buy | $125.0 | rated | Dec 12, 2023 |
| joon lee Truist Financial | Buy | $150.0 | maintained | Dec 7, 2023 |
| marc goodman Leerink Partners | Buy | None | maintained | Dec 7, 2023 |
| joseph thome TD Cowen | Buy | $120.0 | maintained | Dec 5, 2023 |
| charles duncan Cantor Fitzgerald | Buy | $108.0 | reiterated | Aug 22, 2023 |
| yatin suneja Guggenheim | Buy | $110.0 | reiterated | Jun 15, 2023 |
| vikram purohit Morgan Stanley | Hold | $90.0 | maintained | Jun 12, 2023 |
| esther hong Loop Capital Markets | Buy | $95.0 | reiterated | Mar 28, 2023 |
| robert hazlett BTIG | Buy | $98.0 | reiterated | Feb 27, 2023 |
| chris howerton Jefferies | Buy | $95.0 | maintained | Feb 8, 2023 |
| myles minter William Blair | Buy | None | reiterated | Nov 28, 2022 |
| vamil divan Mizuho Securities | Buy | $49.0 | maintained | Jun 27, 2022 |
| danielle brill Raymond James | Buy | $125.0 | reiterated | Dec 16, 2019 |
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
When did it IPO
2015
Staff Count
502
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Herriot Tabuteau M.D.
Market Cap
$3.89B
In 2023, AXSM generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that AXSM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
LOPE-USD
$130.07
COLB-USD
$18.28
EXPO-USD
$76.86
PGNY-USD
$40.78
LNTH-USD
$57.46
NEOG-USD
$17.64
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
